Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Sprengeler

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Current Opinion in Drug Discovery & Development|August 4, 2009
Therapeutic applications and design of mast cell tryptase inhibitorsK D Rice, P A Sprengeler
Current Medicinal Chemistry|February 15, 2001
Perspectives on factor Xa inhibitionR Rai, P A Sprengeler, K C Elrod, et al.
Bioorganic & Medicinal Chemistry|July 1, 1996
The design and synthesis of 2,5-linked pyrrolinones. A potential non-peptide peptidomimetic scaffoldA B Smith, S D Knight, P A Sprengeler, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Neutral inhibitors of the serine protease factor XaW D Shrader, W B Young, P A Sprengeler, et al.
Organic Letters|December 2, 2000
Design, synthesis, and evaluation of a pyrrolinone-based matrix metalloprotease inhibitorA B Smith, T Nittoli, P A Sprengeler, et al.
International Journal of Peptide and Protein Research|December 1, 1993
Design and synthesis of sulfur-free cyclic hexapeptides which contain the RGD sequence and bind to the fibrinogen GP IIb/IIIa receptor. A conformation-based correlation between propensity for imide formation and receptor affinityA Lender, W Yao, P A Sprengeler, et al.
Bioorganic & Medicinal Chemistry|April 13, 1999
Molecular modeling, synthesis, and structures of N-methylated 3,5-linked pyrrolin-4-ones toward the creation of a privileged nonpeptide scaffoldA B Smith, D A Favor, P A Sprengeler, et al.
Chemistry & Biology|April 26, 2000
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activatorB A Katz, R Mackman, C Luong, et al.
Journal of Medicinal Chemistry|November 2, 2001
Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activatorR L Mackman, B A Katz, J G Breitenbucher, et al.
Science (New York, N.Y.)|July 8, 1994
Peptide synthesis catalyzed by an antibody containing a binding site for variable amino acidsR Hirschmann, A B Smith, C M Taylor, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Current Opinion in Drug Discovery & Development|August 4, 2009
Therapeutic applications and design of mast cell tryptase inhibitorsK D Rice, P A Sprengeler
Current Medicinal Chemistry|February 15, 2001
Perspectives on factor Xa inhibitionR Rai, P A Sprengeler, K C Elrod, et al.
Bioorganic & Medicinal Chemistry|July 1, 1996
The design and synthesis of 2,5-linked pyrrolinones. A potential non-peptide peptidomimetic scaffoldA B Smith, S D Knight, P A Sprengeler, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Neutral inhibitors of the serine protease factor XaW D Shrader, W B Young, P A Sprengeler, et al.
Organic Letters|December 2, 2000
Design, synthesis, and evaluation of a pyrrolinone-based matrix metalloprotease inhibitorA B Smith, T Nittoli, P A Sprengeler, et al.
International Journal of Peptide and Protein Research|December 1, 1993
Design and synthesis of sulfur-free cyclic hexapeptides which contain the RGD sequence and bind to the fibrinogen GP IIb/IIIa receptor. A conformation-based correlation between propensity for imide formation and receptor affinityA Lender, W Yao, P A Sprengeler, et al.
Bioorganic & Medicinal Chemistry|April 13, 1999
Molecular modeling, synthesis, and structures of N-methylated 3,5-linked pyrrolin-4-ones toward the creation of a privileged nonpeptide scaffoldA B Smith, D A Favor, P A Sprengeler, et al.
Chemistry & Biology|April 26, 2000
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activatorB A Katz, R Mackman, C Luong, et al.
Journal of Medicinal Chemistry|November 2, 2001
Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activatorR L Mackman, B A Katz, J G Breitenbucher, et al.
Science (New York, N.Y.)|July 8, 1994
Peptide synthesis catalyzed by an antibody containing a binding site for variable amino acidsR Hirschmann, A B Smith, C M Taylor, et al.
Pageof 3